Indication
Primary Immunodeficiency Disease
7 clinical trials
10 products
2 drugs
Clinical trial
Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG in Patients With Primary ImmunodeficiencyStatus: Not yet recruiting, Estimated PCD: 2025-01-08
Product
IVIGProduct
IGSC 20% infusionClinical trial
A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
An Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of the Human Normal Immunoglobulin for Intravenous Administration BT595 as Replacement Therapy in Patients With Primary Immunodeficiency Disease (PID)Status: Completed, Estimated PCD: 2020-04-01
Product
IgG Next GenerationClinical trial
Efficacy, Safety and Pharmacokinetics of Boya Intravenous Immunoglobulin (IVIG) in Participants With Primary ImmunodeficiencyStatus: Not yet recruiting, Estimated PCD: 2025-04-30
Product
Boya IVIGClinical trial
Phase II Trial of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Primary Immune Deficiencies, Immune Dysregulatory Syndromes, and Inherited Bone Marrow Failure Syndromes Using Post-Transplant CyclophosphamideStatus: Recruiting, Estimated PCD: 2024-12-31
Product
AlemtuzumabProduct
FludarabineDrug
MelphalanDrug
cyclophosphamideProduct
TacrolimusProduct
Mycophenolate MofetilClinical trial
B-pVAC-SARS-CoV-2: Phase I/II Multicenter Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults With Bcell/ Antibody DeficiencyStatus: Completed, Estimated PCD: 2022-08-18
Product
CoVAC-1Clinical trial
A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)Status: Recruiting, Estimated PCD: 2026-04-30
Product
Kedrion IVIG 10%